ClinicalTrials.gov
public full text
Public Domain
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 36 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.#845665
- Lubiprostone for Chronic Idiopathic Constipation Treatment#826357
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk#1164245
- Lubiprostone for Treatment of Chronic Idiopathic Constipation#1125333
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation#1262698
Record · ID 1182994
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive